Advancis Pharmaceutical Corporation

Shire Laboratories, Inc.

Pharmavene, Inc.

Shionogi, Inc.

Other

Disposerx, Inc.

Middlebrook Pharmaceuticals, Inc.

Shire Llc, USA

Supernus Pharmaceuticals, Inc.

Victory Pharma, Inc.

Edward M Rudnic

Sandra E Wassink

Donald J Treacy, Jr

James D Isbister

Beth A Burnside

Richard Alan Couch

Charlotte M McGuinness

John A McCarty

Henry H Flanner

Xiaodi Guo

Jill E Pinkett

Rong-Kun Chang

Donald J Treacy

George W Belenduik

George W Belendiuk

Kimberly Fiske

George W Belendiuk, Deceased

Carol E Mattes

John W Holaday

Alexander K Tustian

Donald Treacy

Marcus Schestopol

George Belenduik

Krystyna Belendiuk

Charlotte M McGuiness

James D Isbiter

Charlotte M Mc Guinness

Composition to aid in the sequestration and/or disposal of unused human or animal pharmaceutical drug or medication. The composition comprises a disposal composition material that contains a gelling or massing agent and optionally other components, and can be in the form of pellets, beads, beadlets, granules, or the like. The disposal composition material can be incorporated into a sachet or other disposal container or its cap to prevent the use of the medicament or the removal/extraction of active agent(s) from a pharmaceutical dosage form intended for disposal, to an appreciable extent and/or rate. With in the disposal agent, or fill material there may also be additional ingredients to promote mixing, sequestration or destruction of the active agent. The disposal composition is contained in a sachet and dispensed with a medicament for use when the patient has finished with the medication and there is material left over for disposal. In addition, the sachet could be made available for use with non-prescription drugs and other materials.

Disposal of medicaments

An antibiotic product is comprised of at least two dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as one or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Once a day amoxicillin product comprising immediate and delayed release dosage forms

An antifungal product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antifungal product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antifungal once-a-day product, use and formulation thereof

A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one of a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.

Oral pulsed dose drug delivery system

A multiple pulsed dose drug delivery system for pharmaceutically active amphetamine salts, comprising an immediate-release component and an enteric delayed-release component wherein (1) the enteric release coating has a defined minimum thickness and/or (2) there is a protective layer between the pharmaceutically active amphetamine salt and the enteric release coating and/or (3) there is a protective layer over the enteric release coating. The product can be composed of either one or a number of beads in a dosage form, including either capsule, tablet, or sachet method for administering the beads.

An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antiviral product, use and formulation thereof

An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cfor the anti-fungal product being reached in less than about twelve hours after initial release of anti-fungal from the product.

Multiple-delayed release antifungal product, use and formulation thereof

Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. In a preferred embodiment, release from the second, third and fourth dosage forms is initiated after the component released from the immediately previous form reaches C.

Antibiotic composition with inhibitor

An antineoplastic product is comprised of at least three dosages forms, each of which has a different release profile, with the Cfor the antineoplastic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cat different times.

Antineoplastic product, use and formulation thereof

An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cfor the anti-neoplastic product being reached in less than about twelve hours after initial release of anti-neoplastic from the product.

Multiple-delayed release anti-neoplastic product, use and formulation thereof

An anti-viral product is comprised of at least three delayed release dosage forms, each of which has a different release profile, with the Cfor the anti-viral product being reached in less than about twelve hours after initial release of anti-viral from the product.

Multiple-delayed release anti-viral product, use and formulation thereof

An antibiotic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cfor the antibiotic product being reached in less than about twelve hours.

Multiple-delayed released antibiotic product, use and formulation thereof

Disclosed are antibiotic products for delivering at least two different antibiotics, wherein the products are comprised of at least three or four dosage forms with different release profiles and the at least two different antibiotics comprise at least one protein synthesis inhibiting antibiotic and at least one non-protein synthesis inhibiting antibiotic.

Antibiotic composition

An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.

Growing community of inventors

N. Potomac, MD, United States of America

Edward M Rudnic